Citius Pharmaceuticals Inc

CTXR

Company Profile

  • Business description

    Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

  • Contact

    11 Commerce Drive
    First Floor
    CranfordNJ07016
    USA

    T: +1 908 967-6677

    E: [email protected]

    https://www.citiuspharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    23

Stocks News & Analysis

stocks

Wide moat share remains cheap despite rising costs

Higher costs weigh on profits but stronger sales trends support long term outlook.
stocks

Fair value upgrade for ASX listed fast food chain

Earnings beat lifts forecasts but long term growth questions remain.
stocks

Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?

We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,374.9050.400.54%
CAC 408,439.2013.81-0.16%
DAX 4026,266.14159.540.61%
Dow JONES (US)53,577.40160.240.30%
FTSE 10010,886.1631.840.29%
HKSE25,511.106.23-0.02%
NASDAQ26,151.30171.110.66%
Nikkei 22565,856.43328.340.50%
NZX 50 Index13,992.72110.840.80%
S&P 5007,677.2824.420.32%
S&P/ASX 2009,164.6054.300.60%
SSE Composite Index3,889.447.440.19%

Market Movers